Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @prochigneux
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @prochigneux
-
Le cancer est en forte progression dans le monde — via
@lemondefrhttps://www.lemonde.fr/planete/article/2020/02/04/le-cancer-est-en-forte-progression-dans-le-monde_6028298_3244.html …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Philippe Rochigneux proslijedio/la je Tweet
KRAS mutations in ctDNA correlated with recurrence free & overall survival in
#PancreaticCancer - while the separation of curves is not as impressive as#ColonCancer, this is an opportunity to introduce novel treatments in the MRD setting. https://www.nature.com/articles/s41416-019-0704-2 …#GI20pic.twitter.com/8OvnQlBDgy
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Philippe Rochigneux proslijedio/la je Tweet
From 100 million patient visits, 155,000 doctors, > 400 health systems: Doctors spend > 16 minutes w/ electronic health record per encounter https://annals.org/aim/fullarticle/2758843/physician-time-spent-using-electronic-health-record-during-outpatient-encounters …
@AnnalsofIM (which is more than time spent w/ the patient, much w/ EHR) From@Cerner's@marcoverhage@dmccalliepic.twitter.com/PIGlILsL4G
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Philippe Rochigneux proslijedio/la je Tweet
Larotrectinib shows impressive clinical efficacy in NTRK fusion positive NSCLC! Highlights from our poster presented at
#lung20 shown here. NTRK fusions should be included in molecular screening panels - must not miss!@iaslc@aacr#lcsm@alexdrilonpic.twitter.com/arR1TXXJ8m
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Philippe Rochigneux proslijedio/la je Tweet
Dissecting the mechanisms of immune checkpoint therapyhttp://dlvr.it/RMp3RX
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Philippe Rochigneux proslijedio/la je Tweet
#EditorsChoice@Annals_Oncology | Evidencia actual y desafíos futuros que abordan la eliminación del paradigma de la cirugía de#CáncerDeMama después de la terapia sistémica neoadyuvante |Artículo completo
http://bit.ly/2R7PyqG
@myesmo#bcsm#BreastCancer#Oncología#Surgerypic.twitter.com/yIZJLzSgEE
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Philippe Rochigneux proslijedio/la je Tweet
An important advance for immunotherapy Tom, given the major morbidity associated with Cystectomy- particularly in older patients.https://twitter.com/tompowles1/status/1207069246066483200 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Philippe Rochigneux proslijedio/la je Tweet
#BREAKINGNEWS: The#cancer death rate declined by 29% from 1991-2017, including a 2.2% drop from 2016-2017. The steady 26-year decline is driven by long-term drops in death rates for the four major cancers- lung, colorectal, breast, & prostate. http://bit.ly/39JEpVP pic.twitter.com/N1UsAy8HIgHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Philippe Rochigneux proslijedio/la je Tweet
DS8201 is transforming BC: 60% ORR, 16 month PFS in refractory her2+++. ph III ongoing. next: .combo (parp inh to synergise with dxd , IO because lympho spared of chemo) .early stage to improve dfs AND QOL .her2-low .on treat biopsies for MOA (Daisy trial
)
(COI:res grant)https://twitter.com/NEJM/status/1204750178043006977 …Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Philippe Rochigneux proslijedio/la je Tweet
TMT (= Turb and RTCT)in Bladder Cancer. Reviews by nature Ca https://rdcu.be/bYhSR Personalizedtreatment / biomarkers / QoLpic.twitter.com/uVPxeNWTIA
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Philippe Rochigneux proslijedio/la je Tweet
Happening now!!!! New targeted tx for IDH1-mutated cholangiocarcinoma.
#ivosidenib (AKA#AG120) met its primary endpoint of PFS advantage vs placebo. Congrats to@GABOUALFA, Milind Javle,@AgiosPharma and others. Excited that our global ph I effort materialized in only ~ 5 yearpic.twitter.com/HgDUPjnPNi
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Adding Pembrolizumab to Neoadjuvant Chemotherapy Improves Outcome | ESMO https://www.esmo.org/Oncology-News/Adding-Pembrolizumab-to-Neoadjuvant-Chemotherapy-Improves-Outcome-in-Early-TNBC#.XZD2rZQJlPE.twitter …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Hope to see the combo soraf-nivo in the future. Hopefully not too toxic! Nivolumab Challenges Sorafenib as First-line Treatment | ESMO https://www.esmo.org/Oncology-News/Nivolumab-Challenges-Sorafenib-as-First-line-Treatment-in-Advanced-HCC#.XY5fSBWJxR0.twitter …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Philippe Rochigneux proslijedio/la je Tweet
A mass media promoting a large clinical trial, with two possible implications: a. incite citizen to participate in the trial, b. create awarness and educate.


@LeParisien_75 and@FlorenceMereopic.twitter.com/1HpmRpvpK2
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Philippe Rochigneux proslijedio/la je Tweet
Dr Arjun Saghal
@SahgalArjun presenting a thoughtful discussion of NRG 0631- single fraction spine SBRT did not improve pain at 3 months vs palliative EBRT. Will be interesting to see LC anc retreat rates in the future.#ASTRO19Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Philippe Rochigneux proslijedio/la je Tweet
#ASTRO19#pallonc session: loved this study of patient#outofpocket costs and#financialtoxicity from@MDAndersonNews showing that a rapid access clinic can help with patient financial burden. Specifically 8 Gy x1 was very helpful at reducing costs.pic.twitter.com/8QPHqVCRfK
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Philippe Rochigneux proslijedio/la je Tweet
Larotrectinib in Lung NTRK. N= 12. ORR 75%. High CNS activitypic.twitter.com/7dzEAgGfKm
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Philippe Rochigneux proslijedio/la je Tweet
Data fresh from
at #WCLC19 on added clinical value added of#Sabr for stage IV EGFR+#nsclc. In time for those ready to debate at#ASTRO19 EL9: can RT cure oligometaststic#lungcancer? Keep it coming! See you there!#radonc#lcsmpic.twitter.com/b7hfqasEmk
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Philippe Rochigneux proslijedio/la je Tweet
Update on hyperprogressive disease (HPD)
#WCLC2019 - pts with NSCLC treated w single agent IO
OA14.06 Italy n=257
HPD 20.6%
P1.04.70 South Korea n=73
HPD 12%
P1.04.81 Latin-America n=110
HPD 19.8%
P2.04-77 Canada n=40
HPD 15%
P2.01-46 South Korea n=83
HPD 19.2%Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Philippe Rochigneux proslijedio/la je Tweet
Selpercatinib (formerly LOXO-292) in RET rearranged lung cancer. Results from LIBRETTO-001 Ph1/2 trial. KEY message: A phase 3 RCT is ongoing in this infrequent alteration. Needed? Ethical? Feasible? What do you think?
#LCSM#WCLC19@IASLCpic.twitter.com/ifPJtyeDff
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.